Results 201 to 210 of about 292,858 (349)

A Multiphysics Biventricular Cardiac Model: Simulations With a Left-Ventricular Assist Device

, 2018
Azam Ahmad Bakir, Amr Al Abed, Michael Stevens, Nigel H. Lovell, Socrates Dokos   +4 more
openalex   +1 more source

FMO2 Promotes Angiogenesis via Regulation of N‐Acetylornithine

Advanced Science, EarlyView.
This study identifies flavin‐containing monooxygenase 2 (FMO2) as a novel proangiogenic regulator in endothelial cells. Targeted FMO2 ablation impairs vessel sprouting, whereas its compensation potently enhances angiogenesis. Metabolomics and single‐cell sequencing reveal that FMO2 drives vascular growth via the N‐acetylornithine/ATF3/NOTCH1 axis ...
Jingyi Wang, Yinghui Xu, Xianpeng Wu, Mo Li, Changchen Xiao, Zaiyang Fu, Yongjian Chen, Qingju Li, Yating Ruan, Jing Zhao, Zhiwei Zhong, Jinghai Chen, Wei Zhu, Jinliang Nan, Cheng Ni, Xinyang Hu   +15 more
wiley   +1 more source

PM2.5 Induce Endothelial‐Mesenchymal Transition and Cardiac Fibrosis via the NCOA4‐Mediated Ferritinophagy

Advanced Science, EarlyView.
This study primarily reveals that PM2.5‐derived Fe‐containing particles, particularly magnetite, are specifically enriched in the heart. Here, they interact with NCOA4 in endothelial cells, disrupt iron homeostasis by enhancing ferritinophagy, and subsequently trigger the process of EndMT through the NCOA4/KLF5 pathway.
Qinglin Sun, Mengyuan Wang, Lin Liu, Ruiyang Ding, Kanglin Yan, Shiqian Liu, Xiaoke Ren, Qing Xu, Zhiwei Sun, Qian Liu, Yi Yang, Junchao Duan   +11 more
wiley   +1 more source

A case report: corheart 6 biventricular assist device therapy for end-stage heart failure in dilated cardiomyopathy. [PDF]

Front Cardiovasc Med
Ding Q, Chen C, Xu Z, Zhang N, Pan J, Ge M.   +5 more
europepmc   +1 more source

The Use of Cardiac Resynchronization Therapy in Patients Supported By Continuous-Flow Left Ventricular Assist Device [PDF]

, 2015
A.R. Garan, X. Mai, A.P. Levine, Veli K. Topkara, Sunu S. Thomas, M. Yuzefpolskaya, P.C. Colombo, Donna Mancini, Koji Takeda, Hiroo Takayama, Yoshifumi Naka, Ulrich P. Jorde, Nir Uriel   +12 more
openalex   +1 more source

(12) Post-Stage 2 Palliation Single Ventricular Assist Device Outcomes: An Advanced Cardiac Therapies Improving Outcomes Network (Action) Registry Analysis

, 2023
E.J. Rabinowitz, M. Mehegan, A. Joong, M. Shezad, E. Griffiths, M.J. O'Connor, D. Mokshagundam, A.S. Said   +7 more
openalex   +1 more source

Multiscale Construction, Evaluation, and Application of Organoids

Advanced Science, EarlyView.
Organoids are pivotal models with transformative biomedical potential. A comprehensive multi‐scale perspective is presented, encompassing dual‐scale construction, four‐dimensional evaluation, triple‐point application, and an analysis of the current challenges faced by organoid technology, aiming to advance organoid research and its biomedical ...
Wanting Ma, Zhenglin Dong, Zhu'anzhen Zheng, Long Bai, Xingcai Zhang, Jiacan Su   +5 more
wiley   +1 more source

Role of implantable loop recorders in optimizing care for patients during and after left ventricular assist device support: a single centre experience. [PDF]

BMC Cardiovasc Disord
Emam AY, El Husseny MWA, Ellithy A, Fawzy N, Elghazoly A, Ahmed E, Selwanos PP, Kamel O.   +7 more
europepmc   +1 more source

Microvascular Health as a Key Determinant of Organismal Aging

Advanced Science, EarlyView.
This review spotlights the emerging field of vascular aging, providing a comprehensive and critical overview of the molecular processes and clinical manifestations of vascular dysfunction during aging. By combining basic angioscience concepts with a critical analysis of innovative pre‐clinical aging models and lifestyle interventions, it offers a ...
Mattia Cenciarini, Andrea Uccelli, Francesca Mangili, Myriam Grunewald, Simone Bersini   +4 more
wiley   +1 more source

An Aptamer‐Based EXACT Anticoagulant as a Sustainable, Animal‐Free Alternative to Unfractionated Heparin

Advanced Science, EarlyView.
By simply conjugating thrombin's active‐site inhibitor, dabigatran, with an exosite inhibitor, aptamer HD1, the resulting EXosite‐ACTive site (EXACT) inhibitors show two orders of magnitude higher potency and selectivity via synergistic binding, while maintaining the aptamer's antidote‐reversible trait, yielding a potential substitute for the animal ...
Haixiang Yu, George Pitoc, Manqi Zhang, Jeffrey Clancy, James Frederiksen, Amy Yan, Samuel Francis, Rebecca Sullenger, Rachel Rempel, Susannah Gammell, Jillian Caiazzi, Bruce A. Sullenger   +11 more
wiley   +1 more source